potentially supports cancer care: a systematic review of randomized and non-randomized clinical studies.
메타분석
1/5 보강
[OBJECTIVE] To evaluate effectiveness and safety of in cancer care.
- 연구 설계 case-control
APA
Shen C, Wu XT, et al. (2026). potentially supports cancer care: a systematic review of randomized and non-randomized clinical studies.. Frontiers in nutrition, 13, 1621710. https://doi.org/10.3389/fnut.2026.1621710
MLA
Shen C, et al.. " potentially supports cancer care: a systematic review of randomized and non-randomized clinical studies.." Frontiers in nutrition, vol. 13, 2026, pp. 1621710.
PMID
41909047
Abstract
[OBJECTIVE] To evaluate effectiveness and safety of in cancer care.
[METHODS] PubMed, the Cochrane Library, EMBASE, Web of Science, Scopus and four Chinese databases were searched up to January 9, 2025. Randomized and non-randomized clinical studies, cohort studies, or case-control studies were included for cancer patients using products alone or combined with conventional treatments. Primary outcomes were survival, response rates, and quality of life (QoL). GRADE approach was used to assess evidence certainty.
[RESULTS] Ten studies (seven randomized trials, two non-randomized studies, one cohort study) with 8,898 participants were included. Compared to chemotherapy alone, granules plus chemotherapy improved survival-based effective rate [two studies, risk ratio (RR) 1.55, 95% confidence interval (CI) (1.24, 1.92), low certainty] and QoL-based effective rate [three studies, RR 1.76, 95% CI (1.47, 2.11), low certainty]. The objective response rate (ORR) was improved when chemotherapy was combined with either granules or syrup [four studies, RR 1.88, 95% CI (1.43, 2.48), low certainty]. products (syrup, granules or oral liquid) plus chemotherapy or radiotherapy, all found to have effects in improving immune function as CD4 and CD4/CD8. oral liquid combined with chemotherapy was associated with fewer adverse events, nausea and vomiting, and myelosuppression.
[CONCLUSION] products may improve survival, ORR, QoL and immune function as a complementary add-on therapy. Despite the limited number of studies and low certainty of evidence, the observed signals indicate a need for verification in well-designed, cancer-type-specific trials, particularly in lung cancer, using standardized, well-characterized extracts to establish definitive clinical applications and dosing protocols.
[SYSTEMATIC REVIEW REGISTRATION] The review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO, CRD42025646003).
[METHODS] PubMed, the Cochrane Library, EMBASE, Web of Science, Scopus and four Chinese databases were searched up to January 9, 2025. Randomized and non-randomized clinical studies, cohort studies, or case-control studies were included for cancer patients using products alone or combined with conventional treatments. Primary outcomes were survival, response rates, and quality of life (QoL). GRADE approach was used to assess evidence certainty.
[RESULTS] Ten studies (seven randomized trials, two non-randomized studies, one cohort study) with 8,898 participants were included. Compared to chemotherapy alone, granules plus chemotherapy improved survival-based effective rate [two studies, risk ratio (RR) 1.55, 95% confidence interval (CI) (1.24, 1.92), low certainty] and QoL-based effective rate [three studies, RR 1.76, 95% CI (1.47, 2.11), low certainty]. The objective response rate (ORR) was improved when chemotherapy was combined with either granules or syrup [four studies, RR 1.88, 95% CI (1.43, 2.48), low certainty]. products (syrup, granules or oral liquid) plus chemotherapy or radiotherapy, all found to have effects in improving immune function as CD4 and CD4/CD8. oral liquid combined with chemotherapy was associated with fewer adverse events, nausea and vomiting, and myelosuppression.
[CONCLUSION] products may improve survival, ORR, QoL and immune function as a complementary add-on therapy. Despite the limited number of studies and low certainty of evidence, the observed signals indicate a need for verification in well-designed, cancer-type-specific trials, particularly in lung cancer, using standardized, well-characterized extracts to establish definitive clinical applications and dosing protocols.
[SYSTEMATIC REVIEW REGISTRATION] The review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO, CRD42025646003).
같은 제1저자의 인용 많은 논문 (5)
- Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.
- Overexpression of miR-195-5p Suppresses Gastric Cancer Progression by Regulating LAMP2-Mediated Autophagy.
- The mutational factors influencing the therapeutic response and prognosis of stage IV CRC patients undergoing simultaneous resection of primary and liver metastatic lesions and subsequent adjuvant therapy---A pilot study on the prognosis of stage IV CRC.
- Current Advances in Paraptosis Inducer Development and Mechanistic Understanding for Anticancer Applications.
- "The sky on our shoulders": a qualitative study of family caregivers' psychosocial experiences and unmet palliative care needs in advanced lung cancer.